Transforming A European Mid-Sized Pharma: An Interview With Almirall President Jorge Gallardo
Executive Summary
Spain’s Almirall has taken a step back from the hypercompetitive respiratory market through its deal with AstraZeneca. It was becoming too expensive to compete in primary care against big pharma, says company President Jorge Gallardo. Almirall will use proceeds to chart a future course as a specialty pharma focused on dermatology.